Integrated Generic Platform offering Concept to Commercialization Solutions

Overview

At Cohance, our generic API platform offers an integrated solutions approach, uniquely positioned to serve our global customer base. With 30+ years of rich legacy, backed by deep chemistry capabilities, global regulatory expertise, and reliable supply network, we serve customers across 60+ countries, from 8 cGMP facilities, offering 50+ molecules across various therapeutic areas. We partner with leading pharma innovators and global generics, collaborating across the product lifecyle stage.

 
Generics API Landing Page

Why partner with us?

Generic APIs_LP_Why Coahance

Why partner with us?

  • Integrated Solutions Approach – Unified generic platform offering APIs, Pellets, and Finished Dosage Forms
  • Chemistry at Core – 3 dedicated R&D centres with 150+ R&D strength
  • Global Portfolio – 50+ molecules with customer base across 60+ countries
  • Flexible Offerings – From Catalog to customized solutions
  • Scale and Reliability – 8 cGMP sites offering kilo to multi-ton capacities
  • Regulatory Compliance – Global regulatory accreditations such as USFDA, EU-GMP, ANVISA, PMDA, NPMA, Health Canada, TGA, KFDA, and more

Manufacturing Strengths

Manufacturing Strengths

Scalable Production: Flexible volumes from gram to multi-ton capacity across multiple sites.

GMP-Ready Infrastructure: USFDA-, EMA-, and PMDA-approved sites with validated processes and full traceability.

Technology-Enabled Execution: Flow reactors, high-pressure systems (up to 20 kg/cm²), cryogenic capabilities (-70°C), and automation.

Regulatory Compliance: 200+ DMFs filed globally; extensive experience in audits and global market readiness.

Lifecycle Manufacturing: Support for reprocessing, impurity purge, solvent recovery, and green manufacturing practices.

Our Integrated Capabilities

Scalable
Production

Flexible volumes from gram to multi-ton capacity across multiple sites.

GMP-Ready
Infrastructure

USFDA-, EMA-, and PMDA-approved sites with validated processes and full traceability.

Technology-Enabled
Execution

Flow reactors, high-pressure systems (up to 20 kg/cm²), cryogenic capabilities (-70°C), and automation.

Regulatory
Compliance

200+ DMFs filed globally; extensive experience in audits and global market readiness.

Lifecycle
Manufacturing

Support for reprocessing, impurity purge, solvent recovery, and green manufacturing practices.

APIs

• Partner of choice offering Scale, Compliance, and Reliability
• Deep chemistry capabilities, scalable capacities, and robust regulatory track record
• 1600+ KL operational capacity across 5 cGMP facilities with global accreditations – USFDA, EDQM, PMDA, NMPA, KFDA, ANVISA, and others
• Diverse portfolio of 80+ molecules covering multiple therapeutic areas

PFIs

• Pelletized intermediates for modified-release formulations
• Strong backward integration with in-house APIs
• BE-oriented design; strong regulatory expertise to support global filings
• 830+ MT operational capacity across 2 cGMP facilities

FDFs

• Vertically integrated CMO/CDMO solutions for generic pharma
• Multi-dosage capabilities including Oral Solids, Oral Liquids, Topical Cloths, Semi-solid Topicals, and others
• 3 cGMP facilities with global regulatory accreditations (USFDA, EU-GMP, Health Canada, TGA, etc.)
• Expertise in in-house development, tech-transfer, dossier filing, and lifecycle support

APIs

• Complex chemistries, NCEs, HPAPIs, peptides
• 5+ manufacturing sites | Global DMF filings
• Extensive therapeutic area coverage

PFIs

• Pelletized intermediates for modified-release formulations
• BE-oriented design, multiparticulate expertise
• Strong backward integration with in-house APIs

FDFs

• Oral solids: tablets, capsules, sachets, bilayer, ODTs
• First-to-file & Para IV strategy expertise
• Full tech transfer, dossier filing, and lifecycle support

Process Safety
& Risk Evaluation

State-of-the-art safety studies (RC1, DSC, ARC) to ensure secure scale-up.

Regulatory
Documentation

Comprehensive support for IND, IMPD, and DMF submissions across global markets.

Facilities

Genome Valley R&D Center: 25,000 sq. ft. of dedicated process development and safety labs.

Commercial Manufacturing Sites: Multi-ton capacity, including facilities for HPAPIs, phosphoramidites, and other complex chemistries.

Flow Chemistry Suites: Plug flow reactors, Corning G1 systems, and photo flow platforms.

Why Cohance for Small Molecule Manufacturing?

Purpose-Built Facilities. Global Readiness.

Across India, our specialized sites cater to the entire development and manufacturing lifecycle — spanning R&D labs, kilo-scale units, and commercial-scale infrastructure (>3,000 kL capacity). Select facilities are USFDA-audited and cleared by key global regulators.
  • Dedicated HPAPI & containment suites
  • QbD-driven process & formulation development
  • Oral solids focus with high-containment, novel delivery platforms
  • Integrated tech transfer and regulatory documentation support

Our Integrated Capabilities

APIs

  • Partner of choice offering Scale, Compliance, and Reliability
  • Deep chemistry capabilities, scalable capacities, and robust regulatory track record
  • 1600+ KL operational capacity across 5 cGMP facilities with global accreditations – USFDA, EDQM, PMDA, NMPA, KFDA, ANVISA, and others
  • Diverse portfolio of 50+ molecules covering multiple therapeutic areas

Pellets

  • Pelletized intermediates for modified-release formulations
  • Strong backward integration with in-house APIs
  • BE-oriented design; strong regulatory expertise to support global filings
  • 830+ MT operational capacity across 2 cGMP facilities

FDFs

  • Vertically integrated CMO/CDMO solutions for generic pharma
  • Multi-dosage capabilities including Oral Solids, Oral Liquids, Topical Cloths, Semi-solid Topicals, and others
  • 3 cGMP facilities with global regulatory accreditations (USFDA, EU-GMP, Health Canada, TGA, etc.)
  • Expertise in in-house development, tech-transfer, dossier filing, and lifecycle support

Genome Valley R&D Center

25,000 sq. ft. of dedicated process development and safety labs.

Commercial Manufacturing Sites

Multi-ton capacity, including facilities for HPAPIs, phosphoramidites, and other complex chemistries.

Flow Chemistry Suites

Plug flow reactors, Corning G1 systems, and photo flow platforms.

Facilities

We operate a robust network of cutting-edge small molecule development and manufacturing facilities across India. Our infrastructure spans lab-scale discovery to large-scale commercial manufacturing — enabling faster, flexible, and scalable solutions for your drug development needs.

Genome Valley R&D Center

25,000 sq. ft. of dedicated process development and safety labs.

Commercial Manufacturing Sites

Multi-ton capacity, including facilities for HPAPIs, phosphoramidites, and other complex chemistries.

Flow Chemistry Suites

Plug flow reactors, Corning G1 systems, and photo flow platforms.

Our early-stage R&D and kilo labs are designed to support route scouting, process development, and scale-up studies.

API-R&D-Unit-I,-Genome-Valley

API R&D, Genome Valley
Hyderabad, India

API-R&D-II-Unit,-Ankaleshwar

API R&D, Ankaleshwar
Gujarat, India

Vijaywada API-Unit-I,-Jaggayapet,

API Unit-I, Jaggayapet
Vijayawada, India

API Unit-II, Achutapuram
Vizag, India

API-R&D-II-Unit,-Ankaleshwar

API Unit-III, Ankaleshwar
Gujarat, India

FDF--Unit-III,-Pashamylaram,Telangana,-India

CDMO Unit-III, Pashamylaram
Hyderabad, India

Designed to seamlessly scale from clinical to commercial manufacturing, these facilities are compliant with global regulatory standards including the US FDA.

FDF-Unit-I,-Nacharam

FDF Unit-I, Nacharam
Hyderabad, India

FDF-Unit-II,-Jadcherla

FDF Unit-II, Jadcherla
Hyderabad, India

Designed to seamlessly scale from clinical to commercial manufacturing, these facilities are compliant with global regulatory standards including the US FDA.

FDF-Unit-I,-Nacharam

FDF Unit-I, Nacharam
Hyderabad, India

FDF-Unit-II,-Jadcherla

FDF Unit-II, Jadcherla
Hyderabad, India

FDF--Unit-III,-Pashamylaram,Telangana,-India

FDF Unit-III, Pashamylaram
Hyderabad, India

FDF-Unit-IV,-Shamshabad-Telangana,-India

FDF Unit IV, Shamshabad
Hyderabad, India

FD-R&D,-Nacharam

FDF R&D, Nacharam
Hyderabad, India

Genome Valley R&D Center

25,000 sq. ft. of dedicated process development and safety labs.

Commercial Manufacturing Sites

Multi-ton capacity, including facilities for HPAPIs, phosphoramidites, and other complex chemistries.

Flow Chemistry Suites

Plug flow reactors, Corning G1 systems, and photo flow platforms.

From grams to tons-trust Cohance to deliver your small molecule at scale.

Contact Manufacturing Team

Let’s Shape the Future of Generics - Together
From ideation to commercialization, Cohance’s Generic API platform offers unmatched reliability and integrated support.

Resources

  • Webinar: De-Risking Early-Phase API Development
  • Case Study: Accelerated Scale-Up of a Chiral Intermediate
  • Whitepaper: Green Chemistry in Route Optimization
  • Blog: The Role of Analytical Precision in Small Molecule Success

Resource Highlights

Webinars

Navigating Regulatory Audits in Small Molecule Manufacturing

Whitepapers

Smart Scale-Up Using Flow Chemistry

Case Studies

Seamless Tech Transfer of a Multi-Step Synthesis

Blog

Building Sustainable API Supply Chains

Webinars

Navigating Regulatory Audits in Small Molecule Manufacturing

Whitepapers

Smart Scale-Up Using Flow Chemistry

Case Studies

Seamless Tech Transfer of a Multi-Step Synthesis

Blog

Building Sustainable API Supply Chains

Our Global Accreditations

At Cohance Lifesciences, every facility stands as a testament to our commitment to uncompromised quality. Below is a snapshot of regulatory approvals and certifications across our global network

API Manufacturing Facilities

API Unit I
• US FDA, EU, PMDA, Russia MOH, KFDA, COFEPRIS, CDSCO, DCA, WHO GMP

API Unit II
• EU, DCA

API Unit III
• US FDA, EDQM, PMDA, KFDA, ANVISA, COFEPRIS, CDSCO, DCA

API Unit IV
• US FDA, EU, CDSCO, DCA

API Unit V
• ISO, DCA

FDF Unit I
• US FDA, Health Canada, MHRA, ANVISA, COFEPRIS, Russia MOH, TGA, Philippines FDA, Tanzania FDA, Greece NOM, Uganda NDA, Germany, SFDA, CDSCO, DCA

FDF Unit II
• CDSCO, DCA

CR Bio
• US FDA, DCGI, MOH Turkey, BPFK Malaysia, WHO Geneva, MHRA, GCC, NPRA Malaysia

Unit 1 to Unit 4, and Unit 6
• British Safety Council, International Safety
• ISO 20400:2017, ISO 22301:2019, ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, ISO 50001:2018

Unit 5
• US FDA, DCA, PPD Global Quality Compliance, EU, CDSCO
• ISO 22301:2019, ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, ISO 50001:2018

Casper
• US FDA, DCA

Our ESG Aspirations

Cohance is committed to a sustainable future with ambitious goals:

  • Net-Zero Emissions by 2050: Focusing on decarbonization, renewable energy, and resource efficiency, aligned with Science-Based Targets (SBTi).
  • Environmental Sustainability: Enhancing green practices through sustainable procurement and biodiversity protection.
  • Social Impact: Expanding community engagement in health, sanitation, and water access, while supporting economic development through CSR initiatives.
  • UN SDG Alignment: Contributing to goals like Good Health and Well-Being, Clean Water and Sanitation, and Responsible Consumption and Production.
  • Ethical Governance: Strengthening transparency, ethics, and responsible sourcing through global initiatives like the Pharmaceutical Supply Chain Initiative (PSCI).

At Cohance, ESG is our promise to go above and beyond, shaping a sustainable future for health science through passion, expertise, and unwavering responsibility.

History

Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet

Lorem ipsum

Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet

Experience

Our great team of more than 1400 software experts.

Quick Support

We’ll help you test bold new ideas while sharing your.

Leadership Team

John Smith
CEO
Emma London
Co-Founder
Jessica Brown
Managing Director
Christine Eve
Designer

Sustainability

ESG

Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet 

EHS

Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet 

Quality & Compliance

Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet 

We deal With The Aspects Of Professional IT Services

About us

Engitech is the partner of choice for many of the world’s leading enterprises, SMEs and technology challengers. We help businesses elevate their value through custom software development, product design,

Experience

Our great team of more than 1400 software experts.

Quick Support

We’ll help you test bold new ideas while sharing your.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna.
440
employees from around the world
+ 640
happy clients from largest corporations
+ 0
offices in 6 counties worldwide

We deal With The Aspects Of Professional IT Services

About us

Engitech is the partner of choice for many of the world’s leading enterprises, SMEs and technology challengers. We help businesses elevate their value through custom software development, product design,

UI/UX Design
95%
App Development
82%
Business Growth
90%
Technology Solution
80%

Science & Technology

Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet Lorem ipsum dolor sit amet
John Smith A leading Company

Here’s What’s Happening

From our blog